DNA Topoisomerases and Cancer (Record no. 100831)

000 -LEADER
fixed length control field 03856nam a22004575i 4500
001 - CONTROL NUMBER
control field 978-1-4614-0323-4
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140220083238.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 110919s2012 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781461403234
-- 978-1-4614-0323-4
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-1-4614-0323-4
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Pommier, Yves.
Relator term editor.
245 10 - TITLE STATEMENT
Title DNA Topoisomerases and Cancer
Medium [electronic resource] /
Statement of responsibility, etc edited by Yves Pommier.
264 #1 -
-- New York, NY :
-- Springer New York :
-- Imprint: Springer,
-- 2012.
300 ## - PHYSICAL DESCRIPTION
Extent XII, 444 p.
Other physical details online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
347 ## -
-- text file
-- PDF
-- rda
490 1# - SERIES STATEMENT
Series statement Cancer Drug Discovery and Development
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Introduction and Historical Perspective -- Human DNA topoisomerase I: Structure, Enzymology and Biology -- Mitochondrial topoisomerases -- Structure and mechanism of eukaryotic type IIA topoisomerases -- Essential functions of topoisomerase III in the nucleus and mitochondria -- DNA topoisomerase I and illegitimate recombination -- Topoisomerase-induced DNA damage -- Topoisomerases and carcinogenesis: Topo III and BLM -- Topoisomerase inhibitors: a paradigm for interfacial inhibitors -- Topoisomerase I inhibitors: chemical biology -- Topoisomerase II inhibitors: chemical biology -- Topoisomerase I inhibitors: current use and prospects -- Topoisomerase II inhibitors: current use and prospects -- Transcription stress by camptothecin: mechanism and implication for the drug antitumor activity -- Mechanism regulating cellular responses to DNA topoisomerase I-targeted agents -- Tyrosyl-DNA-phosphodiesterase -- Ubiquitin and ubiquitin-like proteins in repair of topoisomerase-mediated DNA damage -- Repair of topoisomerase II-mediated DNA damage: fixing DNA damage arising from a protein covalently trapped on DNA -- Topoisomerases and Apoptosis -- Index.
520 ## - SUMMARY, ETC.
Summary, etc DNA topoisomerases are present in all living organisms and are essential to maintaining the helical structure of DNA. They are highly relevant for cancer because a number of anti-cancer drugs selectively target two of the human enzymes, DNA topoisomerases I and II. Those drugs convert topoisomerases into cellular poisons by trapping the enzymes as they cleave DNA. The book starts out with a detailed outline of the phyllogeny of the different topoisomerases, continues with recent studies on the crystal structures of the human topoisomerases, and their biochemistry. The following section reviews the chemical biology of the topoisomerase inhibitors used in cancer chemotherapy and the implication of topoisomerases in generating recombinations and DNA damage. The third section summarizes the current use of the various topoisomerase inhibitors in cancer chemotherapy. And finally, the last section includes several chapters describing the DNA repair pathways for topoisomerase-induced DNA damage. This book is intended for students and faculty but also for health care professionals who wish to have a self-contained and up-to-date information on topoisomerases. Chapters have been written by leaders and world reknowned experts in the topoisomerase field.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Toxicology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biomedicine.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer Research.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmacology/Toxicology.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781461403227
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Cancer Drug Discovery and Development
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-1-4614-0323-4
912 ## -
-- ZDB-2-SME

No items available.

2017 | The Technical University of Kenya Library | +254(020) 2219929, 3341639, 3343672 | library@tukenya.ac.ke | Haile Selassie Avenue